Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in third-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results Meeting Abstract
| Authors: | Vergote, I.; Finkler, N.; del Campo, J.; Lohr, A.; Hunter, J.; Matei, D.; Spriggs, D.; Kavanagh, J.; Vermorken, J.; Brown, G. L.; Kaye, S. |
| Abstract Title: | Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in third-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results |
| Meeting Title: | 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 25 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2007 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2007-06-20 |
| Start Page: | 281s |
| Language: | English |
| ACCESSION: | WOS:000455043700014 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2007.25.18_suppl.lba5528 |
| Notes: | Meeting Abstract: LBA5528 -- Source: Wos |
